Therapeutic angiogenesis

Protein and gene therapy delivery strategies

Todd K. Rosengart, Shailen R. Patel, Ronald Crystal

Research output: Contribution to journalArticle

Abstract

Angioplasty and surgical bypass, the primary interventional therapies for the treatment of atherosclerosis, are limited by the development over time of native vessel restenoses and graft occlusions. Furthermore, these therapies are not options for a significant number of individuals in whom the extent of vascular pathology is especially severe or widespread. Angiogenesis, the growth of new vasculature, is a critical biological response to ischemia that provides collateralization, or 'biological revascularization' of vascular obstructions. Therapeutic angiogenesis is a strategy whereby one of several known 'angiogens', mediators that induce angiogenesis, can be administered to augment the native angiogenic processes and enhance the formation of a collateral vasculature. This report describes the techniques available for providing therapeutic angiogenesis, including acute and sustained-release techniques to deliver protein angiogens and a number of gene therapy strategies to deliver genes coding for the angiogens.

Original languageEnglish
Pages (from-to)29-40
Number of pages12
JournalJournal of Cardiovascular Risk
Volume6
Issue number1
Publication statusPublished - 20 Apr 1999
Externally publishedYes

Fingerprint

Genetic Therapy
Proteins
Blood Vessels
Therapeutics
Angioplasty
Atherosclerosis
Ischemia
Pathology
Transplants
Growth
Genes
succinic acid drug combination aspirin

Keywords

  • Angiogenesis
  • Gene therapy
  • Vascular endothelial growth factor

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Therapeutic angiogenesis : Protein and gene therapy delivery strategies. / Rosengart, Todd K.; Patel, Shailen R.; Crystal, Ronald.

In: Journal of Cardiovascular Risk, Vol. 6, No. 1, 20.04.1999, p. 29-40.

Research output: Contribution to journalArticle

Rosengart, Todd K. ; Patel, Shailen R. ; Crystal, Ronald. / Therapeutic angiogenesis : Protein and gene therapy delivery strategies. In: Journal of Cardiovascular Risk. 1999 ; Vol. 6, No. 1. pp. 29-40.
@article{2f772b29a77a49cbb04017c180668346,
title = "Therapeutic angiogenesis: Protein and gene therapy delivery strategies",
abstract = "Angioplasty and surgical bypass, the primary interventional therapies for the treatment of atherosclerosis, are limited by the development over time of native vessel restenoses and graft occlusions. Furthermore, these therapies are not options for a significant number of individuals in whom the extent of vascular pathology is especially severe or widespread. Angiogenesis, the growth of new vasculature, is a critical biological response to ischemia that provides collateralization, or 'biological revascularization' of vascular obstructions. Therapeutic angiogenesis is a strategy whereby one of several known 'angiogens', mediators that induce angiogenesis, can be administered to augment the native angiogenic processes and enhance the formation of a collateral vasculature. This report describes the techniques available for providing therapeutic angiogenesis, including acute and sustained-release techniques to deliver protein angiogens and a number of gene therapy strategies to deliver genes coding for the angiogens.",
keywords = "Angiogenesis, Gene therapy, Vascular endothelial growth factor",
author = "Rosengart, {Todd K.} and Patel, {Shailen R.} and Ronald Crystal",
year = "1999",
month = "4",
day = "20",
language = "English",
volume = "6",
pages = "29--40",
journal = "European Journal of Preventive Cardiology",
issn = "2047-4873",
publisher = "SAGE Publications Ltd",
number = "1",

}

TY - JOUR

T1 - Therapeutic angiogenesis

T2 - Protein and gene therapy delivery strategies

AU - Rosengart, Todd K.

AU - Patel, Shailen R.

AU - Crystal, Ronald

PY - 1999/4/20

Y1 - 1999/4/20

N2 - Angioplasty and surgical bypass, the primary interventional therapies for the treatment of atherosclerosis, are limited by the development over time of native vessel restenoses and graft occlusions. Furthermore, these therapies are not options for a significant number of individuals in whom the extent of vascular pathology is especially severe or widespread. Angiogenesis, the growth of new vasculature, is a critical biological response to ischemia that provides collateralization, or 'biological revascularization' of vascular obstructions. Therapeutic angiogenesis is a strategy whereby one of several known 'angiogens', mediators that induce angiogenesis, can be administered to augment the native angiogenic processes and enhance the formation of a collateral vasculature. This report describes the techniques available for providing therapeutic angiogenesis, including acute and sustained-release techniques to deliver protein angiogens and a number of gene therapy strategies to deliver genes coding for the angiogens.

AB - Angioplasty and surgical bypass, the primary interventional therapies for the treatment of atherosclerosis, are limited by the development over time of native vessel restenoses and graft occlusions. Furthermore, these therapies are not options for a significant number of individuals in whom the extent of vascular pathology is especially severe or widespread. Angiogenesis, the growth of new vasculature, is a critical biological response to ischemia that provides collateralization, or 'biological revascularization' of vascular obstructions. Therapeutic angiogenesis is a strategy whereby one of several known 'angiogens', mediators that induce angiogenesis, can be administered to augment the native angiogenic processes and enhance the formation of a collateral vasculature. This report describes the techniques available for providing therapeutic angiogenesis, including acute and sustained-release techniques to deliver protein angiogens and a number of gene therapy strategies to deliver genes coding for the angiogens.

KW - Angiogenesis

KW - Gene therapy

KW - Vascular endothelial growth factor

UR - http://www.scopus.com/inward/record.url?scp=0032927182&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032927182&partnerID=8YFLogxK

M3 - Article

VL - 6

SP - 29

EP - 40

JO - European Journal of Preventive Cardiology

JF - European Journal of Preventive Cardiology

SN - 2047-4873

IS - 1

ER -